Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-21-019810
Filing Date
2021-08-13
Accepted
2021-08-13 09:35:38
Documents
68
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q atos20210630_10q.htm   iXBRL 10-Q 1029707
2 EXHIBIT 31.1 ex_257531.htm EX-31.1 11925
3 EXHIBIT 31.2 ex_257532.htm EX-31.2 12550
4 EXHIBIT 32.1 ex_257533.htm EX-32.1 6348
5 EXHIBIT 32.2 ex_257534.htm EX-32.2 6893
  Complete submission text file 0001437749-21-019810.txt   4901171

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA atos-20210630.xsd EX-101.SCH 51524
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE atos-20210630_cal.xml EX-101.CAL 31173
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20210630_def.xml EX-101.DEF 329946
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20210630_lab.xml EX-101.LAB 285621
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20210630_pre.xml EX-101.PRE 356851
11 EXTRACTED XBRL INSTANCE DOCUMENT atos20210630_10q_htm.xml XML 670028
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35610 | Film No.: 211170029
SIC: 2834 Pharmaceutical Preparations